Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline

Boyd, Sara E., Livermore, David and Hooper, David C. (2020) Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrobial Agents and Chemotherapy. ISSN 0066-4804

[img] PDF (MBLfinal) - Submitted Version
Restricted to Repository staff only until 20 January 2021.

Download (959kB) | Request a copy

Abstract

Modern medicine is threatened by the global rise of antibiotic resistance, especially among -negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are increasingly disseminated worldwide, though particularly in Asia. Many producers have multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and more encouragingly, MBLs may be less effective agents of carbapenem resistance in vivo, under zinc limitation, than in vitro. Owing to their unique structure and function, and their diversity, MBLs pose a particular challenge for drug development. They evade all recently licensed β-lactam- β-lactamase inhibitor combinations, although several stable agents and inhibitor combinations are at various stages in the pipeline. These potential therapies, along with the epidemiology of producers and current treatment options, are the focus of this review.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 14 Jul 2020 23:50
Last Modified: 18 Aug 2020 23:55
URI: https://ueaeprints.uea.ac.uk/id/eprint/76048
DOI: 10.1128/AAC.00397-20

Actions (login required)

View Item View Item